Post-menopausal Vasomotor Symptoms
3
0
0
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
6 treatments under study, led by Osanetant
Research Leaders
7 sponsors active, led by Nerre Therapeutics Ltd.
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
0.0%
0 terminated out of 3 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
67%
2 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 3 completed trials
Clinical Trials (3)
Evaluation of the Pharmacokinetics and Safety of BAY3427080 (NT-814) in Post-Menopausal Women With Vasomotor Symptoms
Dose-ranging, PK, Safety, Efficacy Study of Osanetant in Patients With Moderate/Severe VMS Associated With Menopause
Comparison of Vascular Findings Between Symptomatic and Asymptomatic Postmenopausal Women Before and During Hormone Therapy (HRT)
Research Network
Common Treatments
- Osanetant1
- 17bestradiol Medroxyprogeterone Acetate1
- 17bestradiol Hemihydrate1
- Placebo Pill Gel1
- 17bestradiol1
Active Sponsors
- Nerre Therapeutics Ltd.1
- University of Helsinki1
- Bayer1
- Finnish Medical Foundation1
- Päivikki and Sakari Sohlberg Foundation, Finland1
Top Investigators
Associate Professor
Spaulding Clinical Research LLC
Related Conditions
- Cardiovascular Disease1